British drugmaker GlaxoSmithKline has rejected a €60 billion takeover bid for its consumer goods division with brands such as Sensodyne and Otrivin as being too low.
GSK said on Saturday that Unilever’s bid was not in the best interests of shareholders. The prospects for partition were also underestimated.
GSK now wants to continue with its ‘Consumer Care’ cross-sectional scheme. It is planned to separate the subsidiary from the traditional pharmaceutical business with medicines and vaccines in the middle of the year. The department contains a wide range of health products such as Dr.
British consumer goods group Unilever – known for brands like Langnese, Knorr and Pfanni – announced on Saturday that the GSK subsidiary would fit nicely into its own portfolio. Whether they agree, is uncertain. It’s unclear if Unilever can increase the offer. According to GSK, the group offered £41.7 billion in cash and £8.3 billion of its stock, making the offer worth £50 billion.
The British newspaper “Sunday Times” was the first to report the plans.
/si/dp/ho
London (dpa-AFX)
Image source: OHN THYS/AFP/Getty Images, JOHN THYS/AFP/Getty Images, BEN STANSALL/AFP/Getty Images
Sylvia Plath writes for Social Post News, covering news, politics, business, technology, sport, entertainment, and lifestyle. She focuses on clear, reliable reporting and useful information, helping readers stay informed about current events, emerging trends, and stories that matter.
More Stories
Colorado Springs Could Gain Second Stop on Colorado’s Front Range Passenger Rail Line Under New Draft Plan
Amazon Prime Day Deals Still Available: More Than 130 Discounts Remain on Apple, Oura, Sony and Other Top Brands
Wealthy families take more risks when it comes to money.